What do recent Polivy (polatuzumab vedotin) trials show for progression-free survival (PFS)?
Based on the information provided here, there isn’t enough detail to confirm whether Polivy’s progression-free survival results have improved in more recent clinical trials. PFS outcomes can vary a lot by study design (line of therapy, comparator, patient risk profile, and follow-up time), so you usually need the specific trial names and the reported PFS numbers to make a meaningful comparison.
Which “recent trials” people usually mean for Polivy, and why PFS can’t be compared without the exact study
When patients and clinicians ask whether Polivy’s PFS has improved, they typically mean comparing:
- Earlier vs later studies in the same setting (for example, same disease subtype and treatment line).
- Trials that update endpoints or follow-up duration (PFS is time-to-event and can change as more patients are followed).
- Different regimens (Polivy plus another drug vs a different partner), which can materially affect PFS.
Without the specific trial(s) and the PFS reported (median PFS and/or hazard ratios, plus follow-up), there’s no reliable way to say PFS has improved.
How to check quickly whether PFS improved: the exact data you’d compare across trials
To determine whether PFS improved, you would compare across the specific trials you care about:
- Median PFS (reported in months)
- PFS rates at a fixed time point (if reported)
- Hazard ratio for progression or death vs control
- Whether the trial is first-line vs relapsed/refractory, and the exact comparator regimen
- Data cutoff/follow-up duration
If you share the trial names, I can answer directly
If you tell me which “recent clinical trials” you mean (e.g., trial ID or the publication year and whether it was R/R DLBCL, first-line, or another setting), I can compare their PFS results and state whether the outcomes look better in the later trial(s).
Sources
No sources were provided in the prompt to cite for Polivy PFS results.